Christoph Lassek

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Monitoring of 30 marker candidates in early Parkinson disease as progression markers

Brit Mollenhauer, Johannes Zimmermann, Friederike Sixel‐Döring et al. · Neurology · 2016 · 155 citations · Full text

Medicine, Neurology, Neuroscience +17

Disposition and Elimination of Meropenem in Cerebrospinal Fluid of Hydrocephalic Patients with External Ventriculostomy

Roland Nau, Christoph Lassek, Martina Kinzig‐Schippers et al. · Antimicrobial Agents and Chemotherapy · 1998 · 60 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +15

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany

Tjalf Ziemssen, Michael Lang, Björn Tackenberg et al. · Neurology Neuroimmunology & Neuroinflammation · 2019 · 35 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17